Lilly's progressive journey and contribution, recognised at the global platform

Announcement

Eli Lilly and Company expressed its double excitement by confirming that it will be showcasing the new data from throughout its breast oncology portfolio and the robust pipeline at the San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas, December 9-12. These new updates mirror the company’s continued chain of progress throughout the major roadways in human epidermal, a hormone receptor-positive (HR+) growth factor, including receptor 2-negative (HER2-) breast cancer. This cancer is the most general and common form of cancer.

Data to grab attention at the SABCS

The first data presentation is regarding Inluriyo (imlunestrant), an estrogen receptor antagonist. Under the late-breaking oral presentation term, the company will present the updated results fetched from the Phase 3 EMBER-3 trial examining Inluriyo alone and the combination with Verzenio (abemaciclib) in patients suffering from metastatic or ER+, HER2-advanced breast cancer. The presentation will highlight a pre-specified interim overall survival (OS ) analysis.

Including the valuable updates on time to chemotherapy (TTC) and progression-free survival (PFS). Alongside the poster presentation will declare the results of a discovery analysis of early fluctuations in correlation to clinical outcomes and circulating tumor DNA (ctDNA).

The second data presentation is regarding Verzenio (abemaciclib), a CDK4/6 inhibitor. In the form of a poster, Lilly will show its results from the subgroup analysis of its dedicated Phase 3 monarchE trial, examining the adjuvant abemaciclib plus endocrine therapy by nodal status in patients experiencing HR+, HER2-high risk early breast cancer. This data further extends the current results at ESMO 2025.

The third data presentation is about LY4064809/ STX-478, the investigational pan-mutant-selective PI3Kα inhibitor. In the form of a poster, the company will share its findings and study details from the PIKALO-1. It’s a running Phase 1/2 study examining LY4064809 alone and separately in combination with CDK4/6 inhibitors and endocrine therapy in patients suffering from PIK3CA-mutant HR+, HER2-advanced breast cancer. Including the updated data on efficacy, safety, analyses, and biomarkers throughout the pre-diabetic, non-diabetic and diabetic subgroups will also be highlighted at the event.

The executive vice president and president of Lilly Oncology, Jacob Van Naarden, said, “We’re proud and delighted to be featured at the SABCS 2025 with our new data throughout our portfolio of approved and investigational breast cancer medicines. The medicines that identify the three most essential biologic key targets in HR+ breast cancer, including PI3K and CDK4/6, and the estrogen receptor.”